Great to present phase 1b data for DLL3 ADC ZL-1310 (zoci) in platinum-refractory neuroendocrine carcinomas at #AACR26. Phase 2 is ongoin...

AACR 2026 现场信号· @ · X·2026-04-22 12:23· 2026-04-22Score60

Body · original

Great to present phase 1b data for DLL3 ADC ZL-1310 (zoci) in platinum-refractory neuroendocrine carcinomas at #AACR26. Phase 2 is ongoing and we are excited to develop this drug further for these difficult to treat populations. @ZaiLab_Global @MSKCancerCenter @MSK_DeptOfMed https://t.co/oZzAU4ndpi

Heat 26 · 21 likes · 1 reply · 4 reposts

Conference abstracts

CT189NCT06885281matched by 代号 ZL-1310

Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors

Rohit Thummalapalli, Ming Lu, Alexander Spira, Amr Mohamed, Rahul Aggarwal, Yu Wang, Namrata Vijayvergia, Jordi Rodon, Andrew Scott Paulson, Pingkuan Zhang, Hui Yang, Yuan Xin, Jingmin Wen, Jie Chen

Read the abstract →

Source: AACR 2026 现场信号 · x.com